AMAR Focused on Phase II Completion During Q1
Amarillo Biosciences Inc. (OTCBB: AMAR) had a busy first quarter focusing on its goal of completing Phase II clinical trials for low-dose oral interferon-alpha treatment of Behcet’s disease and oral warts in HIV positive patients by the end of 2007 or early 2008. The company has obtained U.S. Food and Drug Administration (FDA) Orphan Disease Designation for these diseases and believes this is a faster, less expensive way to obtain FDA approval of low-dose oral interferon-alpha. Amarillo also has three more clinical sites that have agreed to join the six clinical sites currently approved to enroll patients in a study…